CD24 and cancer: As some preclinical studies and clinical data have demonstrated the promise of targeting phagocytosis checkpoints [11, 12], macrophage phagocytosis checkpoints, including CD47, CD24, stanniocalcin 1 (STC1), are potential targets for cancer immunotherapy in patients with advanced cancers [13, 14].